Compare HNNA & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNNA | BEAT |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.4M | 63.5M |
| IPO Year | N/A | 2021 |
| Metric | HNNA | BEAT |
|---|---|---|
| Price | $10.32 | $0.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.9K | ★ 6.3M |
| Earning Date | 12-03-2025 | 11-13-2025 |
| Dividend Yield | ★ 5.50% | N/A |
| EPS Growth | ★ 38.04 | N/A |
| EPS | ★ 1.27 | N/A |
| Revenue | ★ $35,538,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.87 | ★ N/A |
| Revenue Growth | ★ 19.88 | N/A |
| 52 Week Low | $8.43 | $0.54 |
| 52 Week High | $13.88 | $3.48 |
| Indicator | HNNA | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 46.88 | 29.07 |
| Support Level | $9.33 | $0.66 |
| Resistance Level | $10.39 | $0.74 |
| Average True Range (ATR) | 0.32 | 0.17 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 61.47 | 15.08 |
Hennessy Advisors Inc is an investment management company, engaged in the managing and marketing of open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, sectors, and specialty, balanced, and fixed income products. It also provides investment advisory services and shareholder services to the Hennessy Funds which include managing the composition of each fund's portfolio, including the purchase, retention, and disposition of portfolio securities as per the Fund's investment objectives, policies, and restrictions; conducting investment research, and monitoring compliance with each fund's investment restrictions and applicable laws and regulations.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.